Business
Cosmos Health Enters the $163 Billion Global Skincare Market; Sales Already Underway in the United States
CHICAGO, June 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced its entry into the global beauty and personal care market. Sales of a new skincare brand — a premium, Korean-developed collagen-based skincare line — have already commenced in the United States and have been live for over a month. The brand is being introduced through a direct-to-consumer model, beginning in
About this update from Cosmos Health Inc.
CHICAGO, June 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced its entry into the global beauty and personal care market. Sales of a new skincare brand — a premium, Korean-developed collagen-based skincare line — have already commenced in the United States and have been live for over a month. The brand is being introduced through a direct-to-consumer model, beginning in the U.S. with a vision to scale globally. Cosmos Health plans to roll out a series of products, pursuing a multi-brand strategy that extends the Company's portfolio well beyond core healthcare categories and deepens its presence in the high-growth skincare category. The launch marks a key step in Cosmos Health's diversification toward higher-margin products and faster-growing, more lucrative end markets. The global skincare products market was valued at approximately $163 billion in 2026 and is projected to reach roughly $203 billion by 2033, according to Grand View Research, with premium skincare among the fastest-growing segments amid rising consumer demand for science-backed formulations. Greg Siokas, CEO of Cosmos Health, stated: "Entering the global beauty market is a natural extension of our strategy to diversify into higher-margin, high-growth categories. With sales already underway in the United States, a direct-to-consumer model built for global scale, and a multi-brand portfolio of products planned, we believe this new chapter can become a meaningful contributor to our growth.” About Cosmos Health Inc.Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale...
View stock analysis, news, and events for Cosmos Health Inc.